Local treatment in metastatic GIST patients: A multicentre analysis from the Dutch GIST Registry

• Published in: European journal of surgical oncology Vol. 49; no. 9; p. 106942
• Main Authors: Brink, Pien, Kalisvaart, Gijsbert M., Schrage, Yvonne M., Mohammadi, Mahmoud, Ijzerman, Nikki S., Bleckman, Roos F., Wal, Tom, de Geus-Oei, Lioe-Fee, Hartgrink, Henk H., Grunhagen, Dirk J., Verhoef, Cornelis, Sleijfer, Stefan, Oosten, Astrid W., Been, Lukas B., van Ginkel, Robert J., Reyners, An K.L., Bonenkamp, Han J., Desar, Ingrid M.E., Gelderblom, Hans, van Houdt, Winan J., Steeghs, Neeltje, Fiocco, Marta, van der Hage, Jos A.
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.09.2023
• Subjects: Advanced; Gastro-intestinal stromal tumours; GIST; Local treatment; Metastatic; Surgery; Survival; Gastro-intestinal stromal tumours; GIST; Advanced; Surgery; Metastatic; Survival; Local treatment
• ISSN: 0748-7983; 1532-2157
• DOI: 10.1016/j.ejso.2023.05.017

The added value of local treatment in selected metastatic GIST patients is unclear. This study aims to provide insight into the usefulness of local treatment in metastatic GIST by use of a survey study and retrospective analyses in a clinical database. A survey study was conducted among clinical specialists to select most relevant characteristics of metastatic GIST patients considered for local treatment, defined as elective surgery or ablation. Patients were selected from the Dutch GIST Registry. A multivariate Cox-regression model for overall survival since time of diagnosis of metastatic disease was estimated with local treatment as a time-dependent variable. An additional model was estimated to assess prognostic factors since local treatment. The survey's response rate was 14/16. Performance status, response to TKIs, location of active disease, number of lesions, mutation status, and time between primary diagnosis and metastases, were regarded the 6 most important characteristics. Of 457 included patients, 123 underwent local treatment, which was associated with better survival after diagnosis of metastases (HR = 0.558, 95%CI = 0.336–0.928). Progressive disease during systemic treatment (HR = 3.885, 95%CI = 1.195–12.627) and disease confined to the liver (HR = 0.269, 95%CI = 0.082–0.880) were associated with worse and better survival after local treatment, respectively. Local treatment is associated with better survival in selected patients with metastatic GIST. Locally treated patients with response to TKIs and disease confined to the liver have good clinical outcome. These results might be considered for tailoring treatment, but should be interpreted with care because only specific patients are provided with local treatment in this retrospective study.